pharmiweb.com
LEO Pharma has announced encouraging findings from its Phase 2a Mechanism of Action (MoA) trial, showcasing the effects of investigational drug temtokibart in patients with moderate-to-severe atopic dermatitis (AD). The results, presented at the 2024 European Academy of Dermatology and Venereology (EADV) Annual Meeting, reveal that temtokibart, when compared to dupilumab, demonstrated faster and more significant improvements in skin hydration and natural moisturizing factors.
What’s New?
In this trial, researchers investigated how temtokibart’s inhibition of the IL-22RA1 receptor impacts skin health in patients with AD. Temtokibart, administered at 450 mg biweekly, outperformed dupilumab in improving skin hydration and barrier function markers within just one week. Additionally, both drugs showed comparable clinical improvements in eczema severity (EASI) and itch scores by week 16. Notably, the findings suggest that blocking IL-22 helps alleviate skin barrier abnormalities without directly targeting immune cells, revealing a new potential therapeutic pathway for AD.
Why It Matters
These results highlight temtokibart’s potential to address unmet needs in the treatment of atopic dermatitis. With its unique mechanism of action, temtokibart may offer faster relief from the skin barrier dysfunction that characterizes AD, complementing existing therapies like dupilumab, which target Type 2 inflammation. As LEO Pharma continues its research, the drug could become a vital tool not only for dermatology but also for other conditions linked to the IL-22 pathway. With further studies underway and results expected in early 2025, temtokibart may soon offer new hope to patients battling chronic inflammatory skin diseases.